目的：探讨埃克替尼治疗晚期非小细胞肺癌(non-small cell lung cancer，NSCLC)的疗效及毒副作用。方法：回顾性分析未行表皮生长因子酪氨酸激酶抑制剂(EGFR-TKI)治疗的晚期NSCLC患者37例，给予盐酸埃克替尼125 mg，3次/d，口服治疗，直到病变进展或不能耐受。随访12个月，评估疗效并观察药物毒副反应。结果：本组37例患者均可评价疗效，客观缓解率(objective response rate，ORR)为56.7%(21/37)，疾病控制率(disease control rate，DCR)为84.6%(35/37)，中位无进展生存期(median progression free survival，mPFS)为6个月(95%CI：5.27~6.74)。不良反应主要为皮疹和腹泻，多为Ⅰ、Ⅱ度，均可耐受。结论：盐酸埃克替尼治疗晚期肺腺癌安全、有效，不良反应可耐受。
Analysis of icotinib on treatment of 37 cases of advanced non-small cell lung cancer
Objective: To evaluate the curative effect and safety of icotinib on treatment of advanced non-small cell lung cancer. Methods: 37 patients of advanced non-small cell lung cancer without treatment of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) were enrolled in the group. All the patients orally took icotinib 125 mg 3 times a day, until the disease progressed or the patients could not tolerate. Efficacy and drug toxicity was observed after 12 months followed-up. Results: Response could be assessed in all the 37 patients. The objective response rate (ORR) was 56.7% (21/37) and the disease control rate (DCR) was 84.6% (35/37). The main adverse reactions were rash and diarrhea, mostly degree Ⅰ or Ⅱ. Conclusion: Icotinib is an effective drug for the treatment of advanced non-small cell lung cancer, with an advantage of nice durability.